Biotest AG / Forecast 27.05.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Biotest: Forecast for turnover and profit raised Dreieich, 27 May 2008. The Managing Board of Biotest AG raised the company's forecast for turnover and profit in the current year. The Management now expects sales of EUR 420 million in 2008, following EUR 326.4 million in the previous year. Until now the target had been EUR 400 million. Earnings before interest and tax (EBIT) are expected to be by 20% higher than in the previous year. The earlier forecast was a raise by 10%. Disclaimer This document contains future-oriented statements regarding macroeconomic development as well as the business outlook, profitability, financial position and asset situation of Biotest AG and its subsidiaries. These statements are based on the current plans, estimates, forecasts and expectations of the company and therefore are subject to risks and elements of uncertainty, which could lead to significant deviation from the expected development in the actual results. The future-oriented statements are only valid at the time of publication. Biotest does not intend to update the future-oriented statements and does not assume any responsibility for doing this. About Biotest Biotest is a pharmaceutical, biotherapeutic and diagnostics company involved in research and production, specialising in the areas of application of immunology and hematology. In the Pharmaceutical segment Biotest develops and markets immunoglobulin, coagulation factors and albumins that are produced from human blood plasma and can be used to treat diseases of the immune system and the hematopoietic system. In the Biotherapeutic segment Biotest promotes the clinical development of monoclonal antibodies, including those used to treat rheumatism and leukaemia. The Diagnostics segment includes reagents and systems for microbiology that are primarily used for hygiene monitoring, as well as for immunologic diagnostics that, for example, can be applied in blood transfusions and transplants. Biotest employees approximately 1800 people worldwide. Shares of Biotest AG are listed on the SDAX of the Deutsche Börse. Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, Germany, www.biotest.de Dr. Michael Ramroth Tel.: +49 (0) 6103 801-338 Fax: +49 (0) 6103 801-347 E-mail: michael_ramroth@biotest.de WKN, ISIN Common shares: 522720, DE0005227201 WKN, ISIN Preferred shares: 522723, DE0005227235 Quoted: Prime Standard/Amtlicher Handel (official trading) Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart DGAP 27.05.2008 --------------------------------------------------------------------------- Language: English Issuer: Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-8 80 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Forecast for turnover and profit raised
| Source: EQS Group AG